Vijaya Diagnostic Centre Share Price
Sector: Healthcare Facilities
931.95 -2.45 (-0.26%)
- 1D
- 5D
- 1M
- 3M
- 6M
- 1Y
- 5Y
- MAX
Price Range
Today’s Low
921.30
Today’s High
937.20
52 Week Low
725.40
52 Week High
1276.75
930.10 -3.90 (-0.42%)
- 1D
- 5D
- 1M
- 3M
- 6M
- 1Y
- 5Y
- MAX
Price Range
Today’s Low
927.10
Today’s High
937.10
52 Week Low
730.00
52 Week High
1275.00
Key Metrics
- Market Cap (In Cr) 9469.5
- Beta 0.45
- Div. Yield (%) 0.21
- P/B 12.05
- TTM P/E 72.2
- Peg Ratio 7.3
- Sector P/E 22.75
- D/E 0
- Open Price 923.3
- Prev Close 934.4
Vijaya Diagnostic Centre Analysis
Price Analysis
-
1 Week0.31%
-
3 Months0.68%
-
6 Month-12.61%
-
YTD-11.62%
-
1 Year19.01%
Risk Meter
- 61% Low risk
- 61% Moderate risk
- 61% Balanced Risk
- 61% High risk
- 61% Extreme risk
Recos
- Strong Sell
- Sell
- Hold
- Buy
- Strong Buy
Analysts' Views
- Ratings
- Current
- 1 W Ago
- 1 M Ago
- 3 M Ago
- Strong Buy
- 3
- 3
- 3
- 3
- Buy
- 1
- 1
- 2
- 2
- Hold
- 2
- 2
- 2
- 2
- Sell
- 2
- 2
- 0.00
- 0.00
- Strong Sell
- 0.00
- 0.00
- 0.00
- 0.00
- Total
- 8
- 8
- 7
- 7
Vijaya Diagnostic Centre News
Breakout stocks to buy or sell: Sumeet Bagadia recommends 5 shares to buy today
2 min read . 16 Oct 2024Breakout stocks to buy or sell: Sumeet Bagadia recommends five shares to buy
2 min read . 01 Oct 2024Vijaya Diagnostic Centre Q4 Results Live : profit rise by 21.67% YOY
1 min read . 10 May 2024Vijaya Diagnostic Centre Q3 FY24 Results Live: profit rise by 57.96% YoY
1 min read . 07 Feb 2024Vijaya Diagnostic Centre Financials
- INCOME
- BALANCE SHEET
- Cashflow
- Period
- 2025
- Total Revenue
- 681.39
- Selling/ General/ Admin Expenses Total
- 112.15
- Depreciation/ Amortization
- 70.6
- Other Operating Expenses Total
- 211.26
- Total Operating Expense
- 479.8
- Operating Income
- 201.59
- Net Income Before Taxes
- 193.16
- Net Income
- 143.08
- Diluted Normalized EPS
- 13.99
- Period
- 2025
- Total Assets
- 1273.62
- Total Liabilities
- 477.9
- Total Equity
- 795.71
- Tangible Book Valueper Share Common Eq
- 63.78
- Period
- 2025
- Cashfrom Operating Activities
- 224.47
- Cashfrom Investing Activities
- -181.87
- Cashfrom Financing Activities
- -52.05
- Net Changein Cash
- -9.45
- Period
- 2024
- Total Revenue
- 547.81
- Selling/ General/ Admin Expenses Total
- 240.83
- Depreciation/ Amortization
- 57
- Other Operating Expenses Total
- 2.37
- Total Operating Expense
- 385.95
- Operating Income
- 161.85
- Net Income Before Taxes
- 158.68
- Net Income
- 118.83
- Diluted Normalized EPS
- 11.6
- Period
- 2024
- Total Assets
- 982.75
- Total Liabilities
- 325.56
- Total Equity
- 657.19
- Tangible Book Valueper Share Common Eq
- 50.5
- Period
- 2024
- Cashfrom Operating Activities
- 184.93
- Cashfrom Investing Activities
- -142.31
- Cashfrom Financing Activities
- -44.55
- Net Changein Cash
- -1.93
- Period
- 2023
- Total Revenue
- 459.22
- Selling/ General/ Admin Expenses Total
- 215.79
- Depreciation/ Amortization
- 61.72
- Other Operating Expenses Total
- 2.52
- Total Operating Expense
- 338.92
- Operating Income
- 120.31
- Net Income Before Taxes
- 113.51
- Net Income
- 84.63
- Diluted Normalized EPS
- 8.25
- Period
- 2023
- Total Assets
- 853.41
- Total Liabilities
- 308.68
- Total Equity
- 544.73
- Tangible Book Valueper Share Common Eq
- 52.57
- Period
- 2023
- Cashfrom Operating Activities
- 164.61
- Cashfrom Investing Activities
- -109.57
- Cashfrom Financing Activities
- -41.91
- Net Changein Cash
- 13.13
- Period
- 2022
- Total Revenue
- 462.37
- Selling/ General/ Admin Expenses Total
- 185.16
- Depreciation/ Amortization
- 52.69
- Other Operating Expenses Total
- 2.01
- Total Operating Expense
- 311.36
- Operating Income
- 151.01
- Net Income Before Taxes
- 147.38
- Net Income
- 109.68
- Diluted Normalized EPS
- 10.66
- Period
- 2022
- Total Assets
- 713.46
- Total Liabilities
- 245.24
- Total Equity
- 468.22
- Tangible Book Valueper Share Common Eq
- 45.26
- Period
- 2022
- Cashfrom Operating Activities
- 158
- Cashfrom Investing Activities
- -123.06
- Cashfrom Financing Activities
- -30.57
- Net Changein Cash
- 4.36
- Period
- 2021
- Total Revenue
- 376.75
- Selling/ General/ Admin Expenses Total
- 152.03
- Depreciation/ Amortization
- 50.45
- Other Operating Expenses Total
- 1.65
- Total Operating Expense
- 261.22
- Operating Income
- 115.52
- Net Income Before Taxes
- 112.12
- Net Income
- 84.48
- Diluted Normalized EPS
- 8.27
- Period
- 2021
- Total Assets
- 541.24
- Total Liabilities
- 182.23
- Total Equity
- 359.01
- Tangible Book Valueper Share Common Eq
- 34.5
- Period
- 2021
- Cashfrom Operating Activities
- 129.64
- Cashfrom Investing Activities
- -129.76
- Cashfrom Financing Activities
- -48.77
- Net Changein Cash
- -48.88
- Period
- 2020
- Total Revenue
- 338.82
- Selling/ General/ Admin Expenses Total
- 160.82
- Depreciation/ Amortization
- 49.17
- Other Operating Expenses Total
- 1.47
- Total Operating Expense
- 255.37
- Operating Income
- 83.45
- Net Income Before Taxes
- 83.43
- Net Income
- 62.54
- Diluted Normalized EPS
- 6.02
- Period
- 2020
- Total Assets
- 482.26
- Total Liabilities
- 207.71
- Total Equity
- 274.54
- Tangible Book Valueper Share Common Eq
- 26.26
- Period
- 2020
- Cashfrom Operating Activities
- 106.11
- Cashfrom Investing Activities
- -30.62
- Cashfrom Financing Activities
- -29.54
- Net Changein Cash
- 45.95
- Period
- 2019
- Total Revenue
- 292.59
- Selling/ General/ Admin Expenses Total
- 142.43
- Depreciation/ Amortization
- 39.63
- Other Operating Expenses Total
- 1.56
- Total Operating Expense
- 224.09
- Operating Income
- 68.49
- Net Income Before Taxes
- 65.32
- Net Income
- 45.87
- Diluted Normalized EPS
- 4.47
- Period
- 2019
- Total Assets
- 406.43
- Total Liabilities
- 199.05
- Total Equity
- 207.38
- Tangible Book Valueper Share Common Eq
- 19.59
- Period
- 2019
- Cashfrom Operating Activities
- 90.53
- Cashfrom Investing Activities
- -89.85
- Cashfrom Financing Activities
- -7.18
- Net Changein Cash
- -6.5
- Period
- 2025-03-31
- Total Revenue
- 173.24
- Selling/ General/ Admin Expenses Total
- 28.4
- Depreciation/ Amortization
- 18.82
- Other Operating Expenses Total
- 53.81
- Total Operating Expense
- 124.23
- Operating Income
- 49.01
- Net Income Before Taxes
- 47.37
- Net Income
- 34.64
- Diluted Normalized EPS
- 3.44
- Period
- 2025-03-31
- Total Assets
- 1273.62
- Total Liabilities
- 477.9
- Total Equity
- 795.71
- Tangible Book Valueper Share Common Eq
- 63.78
- Period
- 2025-03-31
- Cashfrom Operating Activities
- 224.47
- Cashfrom Investing Activities
- -181.87
- Cashfrom Financing Activities
- -52.05
- Net Changein Cash
- -9.45
- Period
- 2024-12-31
- Total Revenue
- 168.98
- Selling/ General/ Admin Expenses Total
- 28.55
- Depreciation/ Amortization
- 18.3
- Other Operating Expenses Total
- 52.44
- Total Operating Expense
- 120.16
- Operating Income
- 48.83
- Net Income Before Taxes
- 46.7
- Net Income
- 35.16
- Diluted Normalized EPS
- 3.42
- Period
- 2024-12-31
- Period
- 2024-12-31
- Period
- 2024-09-30
- Total Revenue
- 182.95
- Selling/ General/ Admin Expenses Total
- 27.84
- Depreciation/ Amortization
- 16.84
- Other Operating Expenses Total
- 56.14
- Total Operating Expense
- 123.8
- Operating Income
- 59.15
- Net Income Before Taxes
- 57.19
- Net Income
- 41.94
- Diluted Normalized EPS
- 4.08
- Period
- 2024-09-30
- Total Assets
- 1125.3
- Total Liabilities
- 400.42
- Total Equity
- 724.88
- Tangible Book Valueper Share Common Eq
- 56.94
- Period
- 2024-09-30
- Cashfrom Operating Activities
- 125.14
- Cashfrom Investing Activities
- -104.98
- Cashfrom Financing Activities
- -27.74
- Net Changein Cash
- -7.58
- Period
- 2024-06-30
- Total Revenue
- 156.22
- Selling/ General/ Admin Expenses Total
- 27.36
- Depreciation/ Amortization
- 16.63
- Other Operating Expenses Total
- 48.86
- Total Operating Expense
- 111.61
- Operating Income
- 44.6
- Net Income Before Taxes
- 41.9
- Net Income
- 31.35
- Diluted Normalized EPS
- 3.05
- Period
- 2024-06-30
- Period
- 2024-06-30
- Period
- 2024-03-31
- Total Revenue
- 155.21
- Selling/ General/ Admin Expenses Total
- 24.52
- Depreciation/ Amortization
- 16.3
- Other Operating Expenses Total
- 48.76
- Total Operating Expense
- 108.39
- Operating Income
- 46.81
- Net Income Before Taxes
- 43.87
- Net Income
- 33.45
- Diluted Normalized EPS
- 3.26
- Period
- 2024-03-31
- Total Assets
- 982.75
- Total Liabilities
- 325.56
- Total Equity
- 657.19
- Tangible Book Valueper Share Common Eq
- 50.5
- Period
- 2024-03-31
- Cashfrom Operating Activities
- 184.93
- Cashfrom Investing Activities
- -142.31
- Cashfrom Financing Activities
- -44.55
- Net Changein Cash
- -1.93
- Period
- 2023-12-31
- Total Revenue
- 132.69
- Selling/ General/ Admin Expenses Total
- 23.03
- Depreciation/ Amortization
- 14.54
- Other Operating Expenses Total
- 41.37
- Total Operating Expense
- 96.98
- Operating Income
- 35.71
- Net Income Before Taxes
- 34.76
- Net Income
- 25.85
- Diluted Normalized EPS
- 2.67
- Period
- 2023-12-31
- Period
- 2023-12-31
Forecast
Income Sheet (In Cr)
Net Income Vs Revenue
Returns Metrics (In Cr)
ROA Vs ROE
Forecast
Balance Sheet
Asset vs Liability
Forecast
Cash Flow
Operating vs Investing
Vijaya Diagnostic Centre Technical
Moving Average
SMA
- 5 Day915.02
- 10 Day953.7
- 20 Day998.72
- 50 Day1000.09
- 100 Day1033.47
- 300 Day997.13
Vijaya Diagnostic Centre Peers
- Price
- Ratio
- Name
- Latest Price
- Change
- % Change
- 52W High
- 52W Low
- Mkt. Cap
- Dr. Lal Pathlabs
- 2825.65
- -10.85
- -0.38
- 3645
- 2295.1
- 23538.41
- Rainbow Childrens Medicare
- 1357
- 22.9
- 1.72
- 1708.5
- 1079.25
- 13778.54
- Vijaya Diagnostic Centre
- 931.95
- -2.45
- -0.26
- 1276.75
- 725.4
- 9469.5
- Metropolis Healthcare
- 1632
- -27.1
- -1.63
- 2306.85
- 1383.7
- 8373.95
- Healthcare Global Enterprises
- 596.5
- -9.25
- -1.53
- 636.8
- 310.1
- 8364.8
- Name
- P/E (X)
- P/B (X)
- ROE %
- OPM
- Dr. Lal Pathlabs
- 58.29
- 10.83
- 21.87
- 16.8
- Rainbow Childrens Medicare
- 63.2
- 10.86
- 19.88
- 13.8
- Vijaya Diagnostic Centre
- 65.96
- 11.91
- 21.09
- 21.54
- Metropolis Healthcare
- 58.96
- 6.46
- 17.66
- 13.79
- Healthcare Global Enterprises
- 185.28
- 10.19
- -4.88
- -3.5
Vijaya Diagnostic Centre Shareholding
Shareholding Pattern
Shareholding Trend
Shareholding(%) v/s Date
Corporate Actions
- Board Meeting
- AGM
- Dividends
- Bonus
- Split
- Rights
- Meeting Date
- Purpose
- 12-May-25
- Audited Results & Final Dividend
- 12-Feb-25
- Quarterly Results & Others
- 07-Nov-24
- Quarterly Results
- 05-Aug-24
- Quarterly Results
- 08-May-24
- Audited Results & Final Dividend
- 05-Feb-24
- Quarterly Results
- 07-Nov-23
- Quarterly Results
- 09-Aug-23
- Quarterly Results
- 29-May-23
- Audited Results & Dividend
- 13-Feb-23
- Quarterly Results
- Meeting Date
- Announced on
- Purpose
- 25-Apr-25
- 25-Mar-25
- COM
- 06-Sept-24
- 19-Aug-24
- AGM
- 20-Sept-23
- 29-May-23
- AGM
- 28-Sept-22
- 26-May-22
- AGM
- Announced on
- Record Date
- Ex-Dividend
- Dividend Value
- 12-May-25
- -
- -
- 2
- 08-May-24
- 30-Aug-24
- 30-Aug-24
- 1
- 29-May-23
- 13-Sept-23
- 13-Sept-23
- 1
- 26-May-22
- 21-Sept-22
- 20-Sept-22
- 1


